^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    BCL2L10 (BCL2 like 10)

    i
    Other names: BCL2L10, BCL2 Like, BCL2-Like 10 (Apoptosis Facilitator), Anti-Apoptotic Protein NrH, Apoptosis Regulator Bcl-B, Bcl-2-Like Protein 10, Bcl2-L-10, Death Inducer Binding To VBcl-2 And Apaf-1, BCL-B, Diva, BCLB, Boo
    9ms
    Curcumin-Induced Molecular Mechanisms in U-87 MG Glioblastoma Cells: Insights from Global Gene Expression Profiling. (PubMed, Molecules)
    Curcumin, a major phytochemical derived from Curcuma longa, has been shown to enhance the efficacy of chemotherapeutic agents such as doxorubicin, 5-fluorouracil, and cisplatin by overcoming drug resistance, making it a promising adjunct in the treatment of glioblastoma. Several pro-apoptotic and anti-BCL, cell-cycle-regulated genes were modulated following curcumin treatment, emphasizing its potential role in curcumin-mediated anti-tumor effects. This study provides insight into the molecular mechanisms underlying curcumin's action against glioblastoma.
    Journal
    |
    GDF15 (Growth differentiation factor 15) • FASLG (Fas ligand) • TGFB1 (Transforming Growth Factor Beta 1) • BCL2L10 (BCL2 like 10) • FZD2 (Frizzled Class Receptor 2) • TNFSF10 (TNF Superfamily Member 10) • TNFSF4 (TNF Superfamily Member 4) • TNFSF11 (TNF Superfamily Member 11)
    |
    cisplatin • 5-fluorouracil • doxorubicin hydrochloride
    10ms
    Decoding the multifunctional potential of ursolic acid: antioxidant, antiproliferative, molecular dynamics, and biodegradability evaluations of a mangrove-derived terpenoid. (PubMed, J Comput Aided Mol Des)
    In the in silico studies, molecular docking of two ligands, Ursolic acid and Obatoclax, with the Bcl-B protein demonstrated notable binding affinities, with ΔG values of -5.8 kcal/mol and - 6.6 kcal/mol, respectively...Further, BIOWIN™ models indicated that the identified Ursolic Acid is biodegradable in an aerobic environment, underscoring its environmental compatibility. Deciphering the bioactivities of ursolic acid could uncover new therapeutic agents and enhance our understanding of its biodegradable environmental compatibility, revealing the source of already documented pharmacological compounds.
    Journal
    |
    BCL2L10 (BCL2 like 10)
    |
    obatoclax (GX 15-070)
    12ms
    BCL-B Promotes Lung Cancer Invasiveness by Direct Inhibition of BOK. (PubMed, Cells)
    The engagement of endothelial-mesenchymal-transition (EMT) further promotes cancer cell invasiveness in such DTPs. Our results reveal that BCL-B fosters cancer cell aggressiveness by counteracting complete MOMP.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL2L10 (BCL2 like 10)
    1year
    Withania somnifera-derived phytochemicals as Bcl-B inhibitors in cancer therapy: A computational approach from byte to bench to bedside. (PubMed, Biochem Biophys Res Commun)
    The results demonstrated that the selected and prioritized phytochemicals, Withanolide L, Withanolide M, and Withanolide A display comparable efficacy to Obatoclax (CID: 11404337) and other known synthetic, semi-synthetic, and natural inhibitors of Bcl-2 family proteins. These findings establish a strong bench foundation for further experimental validation and bedside application, potentially offering an alternative natural approach to cancer therapy.
    Journal
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL2L10 (BCL2 like 10)
    |
    obatoclax (GX 15-070)
    almost2years
    Comprehensive molecular and immune profiling of triple negative invasive lobular carcinoma (AACR 2024)
    These data suggest that TN-ILC had higher frequency of CDH1, ERBB2, AKT1, ARID1A mutations, higher M2 macrophages and neutrophils and lower M1 macrophages and CD8 T cells infiltration and, lower T cell inflamed signature. High TMB and AR expression can translate into use of immunotherapy (ICI) and AR antagonists in these patients. Additonal analysis to determine the optimal biomarker for ICI response in TN-ILC is needed.
    Tumor mutational burden • PD(L)-1 Biomarker • MSi-H Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • BCL2 (B-cell CLL/lymphoma 2) • ARID1A (AT-rich interaction domain 1A) • CD8 (cluster of differentiation 8) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • MCL1 (Myeloid cell leukemia 1) • LAG3 (Lymphocyte Activating 3) • KMT2C (Lysine Methyltransferase 2C) • CDH1 (Cadherin 1) • BCL2A1 (BCL2 Related Protein A1) • FOXP3 (Forkhead Box P3) • PMAIP1 (Phorbol-12-Myristate-13-Acetate-Induced Protein 1) • BCL2L10 (BCL2 like 10) • BAK1 (BCL2 Antagonist/Killer 1)
    |
    PD-L1 expression • ER positive • TMB-H • MSI-H/dMMR • HER-2 mutation • ARID1A mutation • BCL2 expression • AKT1 mutation • AR expression
    |
    PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP142) Assay
    2years
    Role of BCL-B in Multiple Myeloma (clinicaltrials.gov)
    P=N/A, N=60, Completed, Centre Hospitalier Universitaire de Nice | Unknown status --> Completed
    Trial completion
    |
    BCL2L10 (BCL2 like 10)
    2years
    Risk factors analysis and survival prediction model establishment of patients with lung adenocarcinoma based on different pyroptosis-related gene subtypes. (PubMed, Eur J Med Res)
    In our study, we examined LUAD heterogeneity with reference to pyroptosis and found different prognoses between the two subtypes. And a novel prediction model was constructed to predict the OS of LUAD patients based on different PRGs signatures. The model has shown excellent predictive efficiency through validation.
    Journal
    |
    IL1A (Interleukin 1, alpha) • BCL2L10 (BCL2 like 10) • CCR2 (C-C Motif Chemokine Receptor 2)
    2years
    Molecular dynamics simulations assisted investigation of phytochemicals as potential lead candidates against anti-apoptotic Bcl-B protein. (PubMed, J Biomol Struct Dyn)
    The identified molecules also exhibited specific interactions with critical amino acid residues of the binding cleft, highlighting their potential as lead candidates. Finally, molecular dynamics simulations and MM/PBSA based binding free energy analysis revealed that Enterolactone (CID_114739) and Piperine (CID_638024) molecules were on par with Obatoclax (CID_11404337), which is a known inhibitor of the Bcl-2 family proteins.Communicated by Ramaswamy H. Sarma.
    Journal
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL2L10 (BCL2 like 10)
    |
    obatoclax (GX 15-070)
    2years
    Correlation of Flow Cytometric BCL2 and MCL1 Expression with Cytogenetic Characteristics and Outcome in Multiple Myeloma (ASH 2023)
    Our study demonstrates an objective assessment of BCL2 and MCL1 expression by FCM. BCL2 PC/T,MCL1 PC/T and BCL2 PC /MCL1 PC were significantly higher in myeloma cells compared to non-clonal PCs. Low MCL1 expression or high BCL2/MCL1 ratio was associated with IGH: : CCND1; while strong MCL1 and low BCL2/MCL1 ratio was most frequent in 1q21 amplification.
    IO biomarker
    |
    TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • FGFR3 (Fibroblast growth factor receptor 3) • CCND1 (Cyclin D1) • MCL1 (Myeloid cell leukemia 1) • BCL2L1 (BCL2-like 1) • BCL2L2 (BCL2 Like 2) • BCL2L10 (BCL2 like 10) • NSD2 (Nuclear Receptor Binding SET Domain Protein 2)
    |
    TP53 deletion • BCL2 expression • BCL2 positive • MCL1 expression
    |
    Venclexta (venetoclax)
    over2years
    Comprehensive Molecular and Immunological Characterization of Invasive Ductal Triple-Negative Breast Cancer (SABCS 2023)
    ID TNBC was associated with worse OS compared to ID non-TNBC (mOS: 24.5 vs 54.6 months; HR: 0.5, 95% CI 0.47-0.57; p < 0.00001) but trend towards better survival with pembrolizumab (mOS: 29.4 vs 8.8 month; HR: 0.67, 95% CI 0.28-1.5; p=0.3) treatment... These data indicate that ID TNBC is associated with distinct mutational profile compared to non-TNBC, has increased T cell inflamed score, IFNy score, MHC class I and immune checkpoint gene expression, and differential immune cell infiltration. Interestingly, TNBC was associated with increased M1 and decreased M2M. There is evidence to suggest that transcriptomically defined M1 high tumors are clinically aggressive and have worse OS in TNBC.
    PD(L)-1 Biomarker • BRCA Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • BCL2 (B-cell CLL/lymphoma 2) • HRAS (Harvey rat sarcoma viral oncogene homolog) • RB1 (RB Transcriptional Corepressor 1) • NOTCH1 (Notch 1) • NF1 (Neurofibromin 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CCNE1 (Cyclin E1) • MCL1 (Myeloid cell leukemia 1) • BCL2L1 (BCL2-like 1) • NOTCH2 (Notch 2) • CREBBP (CREB binding protein) • PD-L2 (Programmed Cell Death 1 Ligand 2) • PIK3R1 (Phosphoinositide-3-Kinase Regulatory Subunit 1) • BCL2L11 (BCL2 Like 11) • AKT2 (V-akt murine thymoma viral oncogene homolog 2) • BCL2A1 (BCL2 Related Protein A1) • BCL2L2 (BCL2 Like 2) • HLA-B (Major Histocompatibility Complex, Class I, B) • FANCI (FA Complementation Group I) • FOXP3 (Forkhead Box P3) • NFIB (Nuclear Factor I B) • PMAIP1 (Phorbol-12-Myristate-13-Acetate-Induced Protein 1) • BCL2L10 (BCL2 like 10) • TAP1 (Transporter 1) • BAK1 (BCL2 Antagonist/Killer 1) • BBC3 (BCL2 Binding Component 3)
    |
    PD-L1 expression • EGFR mutation • HRAS mutation • BCL2 expression • MCL1 expression
    |
    PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP142) Assay • MI Tumor Seek™
    |
    Keytruda (pembrolizumab)
    over2years
    Comprehensive Characterization of BCL2 Family Genes in Metaplastic Triple Negative Breast Cancer (SABCS 2023)
    This is the first comprehensive analysis of expression and prognostic role of BCL2 family proteins in MBC. Our data suggest a strong association of higher expression of PMAIP1 with worse MTNBC patient survival, potentially attributed to higher immune checkpoint, stem cell-related genes expression, and higher frequency of PD-L1 positivity in PMAIP1-H tumors. These findings indicate PMAIP1 as a potential prognostic biomarker candidate in MTNBC but needs further validation in large prospective studies Table 1.
    PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • BCL2 (B-cell CLL/lymphoma 2) • PD-1 (Programmed cell death 1) • MCL1 (Myeloid cell leukemia 1) • LAG3 (Lymphocyte Activating 3) • BCL2L1 (BCL2-like 1) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • IDO1 (Indoleamine 2,3-dioxygenase 1) • BCL2L11 (BCL2 Like 11) • IL2 (Interleukin 2) • SOX2 • BAX (BCL2-associated X protein) • BCL2A1 (BCL2 Related Protein A1) • BCL2L2 (BCL2 Like 2) • PMAIP1 (Phorbol-12-Myristate-13-Acetate-Induced Protein 1) • BCL2L10 (BCL2 like 10) • NANOG (Nanog Homeobox) • ALDH1A3 (Aldehyde Dehydrogenase 1 Family Member A3) • BAK1 (BCL2 Antagonist/Killer 1) • BBC3 (BCL2 Binding Component 3)
    |
    BCL2 overexpression • BCL2 expression • BAX expression
    over2years
    Bcl-B: an "unknown" protein of the Bcl-2 family. (PubMed, Biol Direct)
    Bcl-B is considered an antiapoptotic protein, but many reports have revealed its contradictory roles in different cancer types. In this mini-review, we elucidate the functions of Bcl-B in normal conditions and various pathologies, its regulation of programmed cell death, its oncogene/oncosuppressor activity in tumorigenesis, its impact on drug-acquired resistance, and possible approaches to inhibit Bcl-B.
    Review • Journal
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL2L10 (BCL2 like 10)